Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Myeloid 2Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

Cyclophosphamide 143fludarabine phosphate 130Busulfan 109Tacrolimus 94fludarabine 93Mycophenolic Acid 90Whole-Body Irradiation 84Peripheral Blood Stem Cell Transplantation 81Imatinib Mesylate 69Antilymphocyte Serum 67Cyclosporine 66Azacitidine 64Cytarabine 63Methotrexate 60Melphalan 60Filgrastim 50Granulocyte Colony-Stimulating Factor 40Decitabine 40Thiotepa 38thymoglobulin 34Stem Cell Transplantation 34Dasatinib 34Radiotherapy 33nilotinib 31ruxolitinib 28Cord Blood Stem Cell Transplantation 28venetoclax 26Clofarabine 25Specimen Handling 24Methylprednisolone 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × mocetinostat × Myeloid × Clear all
NCT00374296 2015-07-01

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Mirati Therapeutics Inc.

Phase 2 Terminated
35 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00666497 2015-05-08

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Mirati Therapeutics Inc.

Phase 2 Terminated
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡